<DOC>
	<DOCNO>NCT02696031</DOCNO>
	<brief_summary>To demonstrate clinical efficacy , safety tolerability secukinumab compare placebo patient non-radiographic axial spondyloarthritis Week 16 well week 52 long term efficacy safety Week 104 .</brief_summary>
	<brief_title>Study Efficacy Safety Secukinumab Patients With Non-radiographic Axial Spondyloarthritis</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male nonpregnant , nonnursing female patient least 18 year age Diagnosis axial spondyloarthritis accord Ankylosing SpondyloArthritis International Society ( ASAS ) axial spondyloarthritis criterion objective sign inflammation ( magnetic resonance imaging ( MRI ) abnormal Creactive protein ) active axial spondyloarthritis assess total Bath Ankylosing Spondylitis Disease Activity Index &gt; =4 cm Spinal pain measure Bath Ankylosing Spondylitis Disease Activity Index question # 2 ≥ 4 cm ( 010 cm ) baseline Total back pain measure Visual Analogue scale ≥ 40 mm ( 0100 mm ) baseline Patients least 2 different nonsteroidal antiinflammatory drug inadequate response Patients TNFα inhibitor ( one ) must experience inadequate response Patients radiographic evidence sacroiliitis , grade ≥ 2 bilaterally grade ≥ 3 unilaterally Inability unwillingness undergo MRI Chest Xray MRI evidence ongoing infectious malignant process Patients take high potency opioid analgesic Previous exposure secukinumab biologic drug directly target interleukin17 ( IL17 ) IL17 receptor Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non-radiographic spondyloarthritis</keyword>
	<keyword>axial spondyloarthritis</keyword>
</DOC>